Folate-cyclodextrin Conjugate for Targeted Chemotherapy

Zlata Tofzikovskaya; Orla Howe; Mary McNamara; Christine O'Connor

doi:10.21427/4e2c-kz94

Folate-cyclodextrin Conjugate for Targeted Chemotherapy

Zlata Tofzikovskaya
, Orla Howe
, Mary McNamara
, Christine O'Connor

Research output: Contribution to conference › Paper › peer-review

Abstract

A general disadvantage of chemotherapy is that the drugs cannot discriminate between fast-growing cancer cells and normal healthy cells which causes many side-effects such as hair loss. An ideal solution to current methods of chemotherapy would be the development of a carrier for an anticancer drug which would be able to transport the drug and therefore target only cancer cells and release the drug molecules inside the cells. In this work folic acid (FA) is attached to an aminoalkane derivative of b-cyclodextrin (CDEn) with a view to developing novel drug delivery systems for therapeutic purposes. Cytotoxisity of folate-conjugate (CDEnFA) is tested on folate over-expressing cell line (HeLa cells) and folate receptor deficient cell line (A549 cells). EC50 values compared to standard (Cisplatin).

Original language	English
DOIs	https://doi.org/10.21427/4e2c-kz94
Publication status	Published - 2009
Event	The First European Cyclodextrin Conference - Aalborg, Denmark Duration: 1 Oct 2009 → 31 Oct 2009

Conference

Conference	The First European Cyclodextrin Conference
Country/Territory	Denmark
City	Aalborg
Period	1/10/09 → 31/10/09

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

chemotherapy
cancer cells
drug delivery systems
folic acid
aminoalkane derivative
b-cyclodextrin
cytotoxicity
HeLa cells
A549 cells
EC50 values
Cisplatin

Access to Document

10.21427/4e2c-kz94Licence: CC BY-NC-SA

Cite this

@conference{305ce79f671b47cfba3e190d3156f877,

title = "Folate-cyclodextrin Conjugate for Targeted Chemotherapy",

abstract = "A general disadvantage of chemotherapy is that the drugs cannot discriminate between fast-growing cancer cells and normal healthy cells which causes many side-effects such as hair loss. An ideal solution to current methods of chemotherapy would be the development of a carrier for an anticancer drug which would be able to transport the drug and therefore target only cancer cells and release the drug molecules inside the cells. In this work folic acid (FA) is attached to an aminoalkane derivative of b-cyclodextrin (CDEn) with a view to developing novel drug delivery systems for therapeutic purposes. Cytotoxisity of folate-conjugate (CDEnFA) is tested on folate over-expressing cell line (HeLa cells) and folate receptor deficient cell line (A549 cells). EC50 values compared to standard (Cisplatin).",

keywords = "chemotherapy, cancer cells, drug delivery systems, folic acid, aminoalkane derivative, b-cyclodextrin, cytotoxicity, HeLa cells, A549 cells, EC50 values, Cisplatin",

author = "Zlata Tofzikovskaya and Orla Howe and Mary McNamara and Christine O'Connor",

year = "2009",

doi = "10.21427/4e2c-kz94",

language = "English",

note = "The First European Cyclodextrin Conference ; Conference date: 01-10-2009 Through 31-10-2009",

}

TY - CONF

T1 - Folate-cyclodextrin Conjugate for Targeted Chemotherapy

AU - Tofzikovskaya, Zlata

AU - Howe, Orla

AU - McNamara, Mary

AU - O'Connor, Christine

PY - 2009

Y1 - 2009

N2 - A general disadvantage of chemotherapy is that the drugs cannot discriminate between fast-growing cancer cells and normal healthy cells which causes many side-effects such as hair loss. An ideal solution to current methods of chemotherapy would be the development of a carrier for an anticancer drug which would be able to transport the drug and therefore target only cancer cells and release the drug molecules inside the cells. In this work folic acid (FA) is attached to an aminoalkane derivative of b-cyclodextrin (CDEn) with a view to developing novel drug delivery systems for therapeutic purposes. Cytotoxisity of folate-conjugate (CDEnFA) is tested on folate over-expressing cell line (HeLa cells) and folate receptor deficient cell line (A549 cells). EC50 values compared to standard (Cisplatin).

AB - A general disadvantage of chemotherapy is that the drugs cannot discriminate between fast-growing cancer cells and normal healthy cells which causes many side-effects such as hair loss. An ideal solution to current methods of chemotherapy would be the development of a carrier for an anticancer drug which would be able to transport the drug and therefore target only cancer cells and release the drug molecules inside the cells. In this work folic acid (FA) is attached to an aminoalkane derivative of b-cyclodextrin (CDEn) with a view to developing novel drug delivery systems for therapeutic purposes. Cytotoxisity of folate-conjugate (CDEnFA) is tested on folate over-expressing cell line (HeLa cells) and folate receptor deficient cell line (A549 cells). EC50 values compared to standard (Cisplatin).

KW - chemotherapy

KW - cancer cells

KW - drug delivery systems

KW - folic acid

KW - aminoalkane derivative

KW - b-cyclodextrin

KW - cytotoxicity

KW - HeLa cells

KW - A549 cells

KW - EC50 values

KW - Cisplatin

U2 - 10.21427/4e2c-kz94

DO - 10.21427/4e2c-kz94

M3 - Paper

T2 - The First European Cyclodextrin Conference

Y2 - 1 October 2009 through 31 October 2009

ER -

Folate-cyclodextrin Conjugate for Targeted Chemotherapy

Abstract

Conference

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this